Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

In this randomized study, the addition of lixisenatide, a glucagon-like peptide 1–receptor agonist, to usual care in patients with type 2 diabetes and a recent cardiovascular event did not alter the rate of subsequent major cardiovascular or other serious adverse events. Randomized trials involving...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The New England journal of medicine Ročník 373; číslo 23; s. 2247 - 2257
Hlavní autori:	Pfeffer, Marc A, Claggett, Brian, Diaz, Rafael, Dickstein, Kenneth, Gerstein, Hertzel C, Køber, Lars V, Lawson, Francesca C, Ping, Lin, Wei, Xiaodan, Lewis, Eldrin F, Maggioni, Aldo P, McMurray, John J.V, Probstfield, Jeffrey L, Riddle, Matthew C, Solomon, Scott D, Tardif, Jean-Claude
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Massachusetts Medical Society 03.12.2015
Predmet:	Acute Coronary Syndrome - complications Acute Coronary Syndrome - drug therapy Acute coronary syndromes Aged Angina Angina, Unstable - complications Cardiovascular diseases Cardiovascular Diseases - epidemiology Cardiovascular Diseases - prevention & control Cerebral infarction Clinical trials Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - mortality Drug dosages Drug therapy Female GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Glucagon-Like Peptide-1 Receptor - agonists Glucose Glycated Hemoglobin A - analysis Heart diseases Heart failure Heart rate Hemoglobin Humans Hypersensitivity Hypoglycemia Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Kaplan-Meier Estimate Male Middle Aged Morbidity Mortality Myocardial infarction Myocardial Infarction - complications Pancreas Pancreatic cancer Pancreatitis Peptides - adverse effects Peptides - therapeutic use Proportional Hazards Models Regulatory approval Treatment Failure
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!